1.Baysal M, Alkış N, Tosun S. Signet ring cell carcinoma metastasis in the bone marrow accompanied by cancer related thrombotic microangiopathy as a first presentation. Nigerian Journal of Clinical Practice. 2022 Feb 1;25(2):211.
2.Shin SY, Park H, Chae SW, Woo HY. Microangiopathic hemolytic anemia as the first manifestation of metastatic signet ring cell carcinoma of unknown origin: a case report and review of literature. The Korean Journal of Laboratory Medicine. 2011 Jul 1;31(3):157-61.
3.Hilgard P and Gordon-Smith EC. Microangiopathic haemolytic anaemia and experimental tumour-cell emboli. Br J Haematol 1974;26:651-9.
4.Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002;4:465-73.
5.Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: Clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 2012;91:195-205.
6.Spoormans I, Altintas S, Van den Brande J, Luijks A, Vermorken JB. Purpura in a patient with disseminated breast cancer: a rapidly progressive cancer-related thrombotic thrombocytopenic purpura. Annals of oncology. 2008 Jun 1;19(6):1204-7.
7.Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases. The Oncologist. 2007 Jan;12(1):11-9.
8.Masias C, Vasu S, Cataland SR. None of the above: Thrombotic microangiopathy beyond TTP and HUS. Blood 2017;129:2857-63.
9.Vasko R, Koziolek M, Fuzesi L, Konig F, Strutz F, Muller GA. Fulminant plasmapheresis-refractory thrombotic microangiopathy associated with advanced gastric cancer. Ther Apher Dial 2010;14:222-5.
10.Howard MA, Williams LA, Terrell DR et al. Complications of plasma exchange in patients treated for clinically suspected thrombotic throm- bocytopenic purpura-hemolytic uremic syndrome. III. An additional study of 57 consecutive patients, 2002–2005. Transfusion 2006;46: 154 –156.